MGROF Stock Chart & Stats
$0.37
-$0.01(-0.89%)
At close: 4:00 PM EST
$0.37
-$0.01(-0.89%)
Day’s Range― - ―
52-Week Range$0.23 - $0.68
Previous CloseN/A
Volume1.18K
Average Volume (3M)1.39K
Market Cap
$16.10M
Enterprise Value$32.96
Total Cash (Recent Filing)$419.58K
Total Debt (Recent Filing)$553.41K
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding62,959,820
10 Day Avg. Volume705
30 Day Avg. Volume1,394
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)39.49
Price to Sales (P/S)4.13
P/FCF Ratio-5.22
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.05
Revenue Forecast (FY)$18.39M
Bulls Say, Bears Say
Bulls Say
Business Model AlignmentMustGrow's product focus is on plant-derived biologics for crop protection and soil health. That aligns with a durable shift toward sustainable, bio-based agricultural inputs, giving the company a structurally relevant addressable market if it can commercialize and scale its technologies.
Moderate LeverageLeverage appears moderate with debt below equity (D/E ~0.67), which reduces immediate solvency strain relative to highly leveraged peers. This provides some financial flexibility over the medium term while management pursues revenue recovery or partnership-led growth.
Proven Revenue Generation HistoricallyThe firm has demonstrated the ability to generate material revenue in prior periods (notably 2023–2025), indicating product-market fit and commercialization capability. This historical scale suggests recovery is feasible if product demand and go-to-market execution improve.
Bears Say
Sharp Revenue DeclineA ~44% TTM revenue drop materially weakens the growth trajectory and reduces scale benefits. Persistent top-line volatility makes forecasting and investment planning difficult, increasing reliance on new product approvals, partnership deals, or sustained market recovery to restore revenues.
Deep Negative MarginsExtremely negative operating and net margins indicate the current cost structure is unsustainable at recent revenue levels. Even if revenue rebounds, margins must improve materially via pricing, mix, or cost control to reach durable profitability and rebuild shareholder equity.
Persistent Cash Burn & Equity ErosionConsistent negative operating and free cash flow (TTM ~ -$3.8M and -$5.3M) and materially eroded equity reduce the company's financial runway. Ongoing cash burn increases dependence on external financing, diluting optionality and heightening execution risk over the medium term.
MustGrow Biologics News
MGROF FAQ
What was MustGrow Biologics’s price range in the past 12 months?
MustGrow Biologics lowest stock price was $0.23 and its highest was $0.68 in the past 12 months.
What is MustGrow Biologics’s market cap?
MustGrow Biologics’s market cap is $16.10M.
When is MustGrow Biologics’s upcoming earnings report date?
MustGrow Biologics’s upcoming earnings report date is Aug 20, 2026 which is in 27 days.
How were MustGrow Biologics’s earnings last quarter?
Currently, no data Available
Is MustGrow Biologics overvalued?
According to Wall Street analysts MustGrow Biologics’s price is currently Overvalued.
Does MustGrow Biologics pay dividends?
MustGrow Biologics does not currently pay dividends.
What is MustGrow Biologics’s EPS estimate?
MustGrow Biologics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MustGrow Biologics have?
MustGrow Biologics has 62,959,820 shares outstanding.
What happened to MustGrow Biologics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MustGrow Biologics?
Currently, no hedge funds are holding shares in MGROF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MustGrow Biologics
MustGrow Biologics Corp. is an agricultural biotechnology enterprise specializing in the creation and commercialization of natural crop protection solutions. These offerings, including biopesticides, biofumigants, and bioherbicides, are uniquely derived from mustard seed. The company provides a pre-planting soil biofumigation technique aimed at combating soil-borne diseases and pests across diverse agricultural commodities, such as fruits and vegetables. Furthermore, MustGrow is actively developing a bioherbicide to manage undesirable plant growth, intended for use in organic farming, home gardens, and broader agricultural sectors. Their portfolio also extends to post-harvest food preservation, applying treatments to inhibit sprouting, disease, and pathogens, thereby enhancing the shelf life of stored products. A significant offering is CannaPM, an active compound effective against both fungal soil ailments and foliar diseases. Established in 2014 and headquartered in Saskatoon, Canada, the company adopted the name MustGrow Biologics Corp. in March 2018, having previously operated as Duport Capital Ltd.
Technical Analysis
Progressive Planet Solutions Inc
―
Bee Vectoring Technologies International
―
Gensource Potash
―
Verde Agritech
―
Nutrien
―